甲基转移酶样蛋白3在结直肠癌化疗耐药中的作用研究进展

Research Progress on the Role of Methyltransferase-like Protein 3 in Chemotherapy Resistance of Colorectal Cancer

目的:结直肠癌是常见的消化道恶性肿瘤,提高结直肠癌疗效是重要的临床问题。近年来,表观遗传修饰相关机制在肿瘤进展及耐药中的作用日渐受到关注,靶向表观遗传改变可能逆转化疗耐药。甲基转移酶样蛋白3(METTL3)作为表观遗传修饰最常见的RNA甲基化转移酶,在结直肠癌化疗耐药中的作用值得进一步探究。该文将有关METTL3表达与化疗耐药现状及DNA修复损伤、细胞自噬、代谢紊乱等经典机制的研究进展作一综述。

Colorectal cancer is a common malignant tumor of digestive tract.Improving the curative effect of colorectal cancer is an important clinical problem.In recent years,the role of epigenetic modification mechanisms in tumor progression and drug resistance has attracted increasing attention,and targeting epigenetic changes may reverse chemotherapy resistance.Methyltransferase-like protein 3(METTL3)is the most common RNA methyltransferase with epigenetic modification,and its role in chemotherapy resistance of colorectal cancer deserves further investigation.In this review,the status quo of METTL3 expression and chemotherapy resistance were reviewed,as well as the research progress of classical mechanisms such as DNA repair damage,autophagy and metabolic disorders.